In particular, accumulated data including our study verify that EZH2 is highly abundant in GBM samples and that expression levels of EZH2 are positively correlated with GBM grades and unfavorable survival [6, 7], which is therefore suggested as a biomarker for diagnosis and prognosis. This evidence concerns the gene EZH2 and glioblastoma.